四种不同方案治疗晚期非小细胞肺癌的疗效比较

Evaluation of the effects of different chemotherapeutic regimens on the treatment of advanced non-small cell lung cancer

目的 比较CAP、EP、MVP和VIP四种不同方案治疗晚期非小细胞肺癌的效果。方法统计学分析各应用回顾性分析,总结出每个方案的近期和远期疗效,做统计学处理。结果 近期疗效:四种方案的有效率分别为CAP 32.1％、EP 37.8％、MVP 46.3％、VIP 52.5％,经组间比较,P值均>0.05,差异无显著性。远期疗效:有效病例治疗后中位生存期分别为CAP 7.8个月、EP 8.0个月、MVP10.0个月和VIP 10. 8个月。毒副反应:骨髓抑制方面以VIP为重,EP最轻。消化道反应以CAP和VIP为重,MVP最轻。结论 四种方案治疗晚期非小细胞肺癌,有效率各组间差异无显著性。但以VIP和MVP的有效率更高,中位生存期更长,仍可作为首选方案。EP方案的毒副反应较轻,适用于全身状况较差、体质较弱的患者。

Objective To assess the antitumor effects of 4 different chemotherapeutic regimens CAP,EP, MVP and VIP on advanced non-small cell lung cancer.Methods Short-term and long-term results of these 4 different chemotherapeutic regimens were analysed retrospectively. Results The short-term effective rates of the 4 regimens were 32.1% ,37.8% ,46.3% and 52.5% for CAP,EP,MVP and VIP,respectively.There were no statistically significant differences between these regimens(P> 0.05) .For long-term effects, the median survival time of effective cases was 7.8 months for CAP,8.0 months for EP, 10.0 months for MVP and 10.8 months for VIP. Myelosuppression of VIP regiment was most serious. Gastrointestinal tract reaction of CAP and VIP regiments was more serious than that of EP and MVP. Conclusion The results show that the short-term results of the 4 regimens have no significant difference. However, the response rates of VIP and MVP regimens are higher than that of EP and CAP,and the survival time of patients treated with these regimens was longer. VIP and MVP regimens should be used as the first-line regimens. EP regimen has few side-effects and is suitable for patients with weak constitution.